News Lupin settles Myrbetriq patent spat with Astellas for $90m Lupin will be able to keep its generic of Astellas' overactive bladder therapy Myrbetriq on the US market, after reaching a settlement agreement.
News 'Skinny' generic Vascepa label case reaches US Supreme Court SCOTUS has agreed to hear a patent dispute between Amarin and Hikma that could have implications for 'skinny labels' used by generic manufacturers.
News Eisai settles Lenvima patent dispute with Torrent Pharma A settlement between Eisai and Torrent Pharma will keep a generic version of blockbuster cancer drug Lenvima off the US market until 2030.
News "Significant shift" as NICE widens prostate cancer drug use NICE has changed unpopular guidance on abiraterone for hormone-sensitive prostate cancer after the entry of generics into the UK market.
News Novartis' new drugs outweigh Entresto decline in Q3 Now feeling the impact of generic competition on its top product Entresto in the US, Novartis is still looking for pipeline-building deals, says CEO.
News AbbVie lifted by lengthy delay to generics of Rinvoq Shares in AbbVie were lifted today after the company revealed that it has settled patent litigation with generic drugmakers on blockbuster Rinvoq.
News White House drops Heidi Overton pick for FDA chief At the eleventh hour, the White House has rescinded its nomination of Heidi Overton – a staunch Trump ally – to be FDA Commissioner.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.